Prognostic factors in patients in the terminal phase of haematological malignancies who are receiving home medical care

Br J Haematol. 2023 Apr;201(2):290-301. doi: 10.1111/bjh.18623. Epub 2022 Dec 26.

Abstract

Although there are many prognostic models for patients in the terminal phase of solid tumours, a reliable prognostic scoring system in patients in the terminal phase of haematological malignancies (HM) has not been established. We retrospectively evaluated 180 patients in the terminal phase of HM who were receiving home medical care (HMC). Multivariate analyses revealed that clinician's estimate, consciousness, loss of appetite, dyspnoea, neutrophil count, lymphocyte count, and lactate dehydrogenase were associated with overall survival (OS). Based on this result, we developed a novel prognostic scoring system, the Japan palliative haematological oncology prognostic estimates, in which four risk groups were shown to clearly differ in survival (p < 0.001): a low-risk group (n = 41, median OS of 434 days), an intermediate-low-risk group (n = 80, median OS of 112 days), an intermediate-high-risk group (n = 38, median OS of 31.5 days), and a high-risk group (n = 21, median OS of 10 days). This is the first investigation of prognostic factors that influence the OS of patients in the terminal phase of HM who are receiving HMC. Providing patients with reliable information about their prognosis is important for them to consider how to spend their remaining life.

Keywords: JPHOPE; Japan palliative haematological oncology prognostic estimates; haematological malignancies; home medical care; prognostic factors; quality of life.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hematologic Neoplasms* / therapy
  • Humans
  • Neoplasms*
  • Prognosis
  • Retrospective Studies
  • Risk Factors